Edinburgh Research Explorer

Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic pituitary-adrenal axis function

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI30982

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Clinical Investigation

Publisher Rights Statement:
Available under Open Access

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function

Annick de Vries,1 Megan C. Holmes,1 Areke Heijnis,1 Jürgen V. Seier,2 Joritha Heerden,2 Johan Louw,2 Sonia Wolfe-Coote,2 Michael J. Meaney,3 Naomi S. Levitt,4 and Jonathan R. Seckl1

1Endocrinology Unit, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, United Kingdom. 2Primate Unit, Diabetes Research Group, South African Medical Research Council, Cape Town, South Africa. 3Douglas Hospital Research Center, McGill University, Montreal, Quebec, Canada. 4Endocrine and Diabetes Unit, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Prenatal stress or glucocorticoid administration has persisting “programming” effects on offspring in rodents and other model species. Multiple doses of glucocorticoids are in widespread use in obstetric practice. To examine the clinical relevance of glucocorticoid programming, we gave 50, 120, or 200 μg/kg/d of dexamethasone (dex50, dex120, or dex200) orally from mid-term to a singleton-bearing nonhuman primate, Chlorocebus aethiops (African vervet). Dexamethasone dose-dependently reduced maternal cortisol levels without effecting maternal blood pressure, glucose, electrolytes, or weight gain. Birth weight was unaffected by any dexamethasone dose, although postnatal growth was attenuated after dex120 and dex200. At 8 months of age, dex120 and dex200 offspring showed impaired glucose tolerance and hyperinsulinemia, with reduced (approximately 25%) pancreatic β cell number at 12 months. Dex120 and dex200 offspring had increased systolic and diastolic blood pressures at 12 months. Mild stress produced an exaggerated cortisol response in dex200 offspring, implying hypothalamic-pituitary-adrenal axis programming. The data are compatible with the extrapolation of the glucocorticoid programming hypothesis to primates and indicate that repeated glucocorticoid therapy and perhaps chronic stress in humans may have long-term effects.

Introduction

Environmental signals during prenatal development often produce structural and functional effects that persist for the lifespan. Such effects are commonly dubbed fetal “programming.” Studies of fetal programming could potentially explain human epidemiological findings indicating that low birth weight and other markers of an adverse intrauterine environment associate with a substantially greater incidence of cardiovascular, metabolic, and neuroendocrine disorders in later life (1–5).

We originally hypothesized that antenatal exposure to excess glucocorticoids might underpin the links between low birth weight and subsequent adult pathophysiology (6). We and others demonstrated that treatment of pregnant rats with the synthetic glucocorticoid dexamethasone, which readily crosses the placenta, recapitulates the major phenotypic outcomes associated with low birth weight. Thus, prenatal exposure to a dose of dexamethasone that only modestly reduces birth weight and does not affect litter size or gestational length causes permanent hypertension, hyperglycemia, hyperinsulinemia, increased hypothalamic-pituitary-adrenal (HPA) axis activity, and anxiety-like behavior in adult offspring (7–14). These effects are most marked with corticoste-

Nonstandard abbreviations used: dex50, 50 μg/kg/d dexamethasone; dex120, 120 μg/kg/d dexamethasone; dex200, 200 μg/kg/d dexamethasone; GR, glucocorticoid receptor; HPA, hypothalamic-pituitary-adrenal; 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; PEPCK, phosphoenolpyruvate carboxykinase; THF, tetrahydrocortisone; TTH, tetrahydrocortisone.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 117:1058–1067 (2007). doi:10.1172/JCI30982.

roid treatment in the last third of gestation (15). Similar effects of dexamethasone and related glucocorticoids have been reported in sheep, pigs, and guinea pigs (16–20). Although the precise timing of the developmental period of glucocorticoid sensitivity varies among species, the outcomes are broadly similar.

These effects of dexamethasone appear to be physiologically relevant. Treatment of pregnant rats with carbadoxolone, an inhibitor of fetoplacental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which protects the fetus from exposure to maternal physiological glucocorticoids, recapitulates the effects of dexamethasone (11). 11β-HSD2−/− mice show reduced birth weight and programmed anxiety (21, 22). Similarly, chronic stress produces elevations of glucocorticoids in the mother and fetus, with a coincidental reduction in placental 11β-HSD2 (23). Predictably, maternal stress programs cardiometabolic and neuroendocrine outcomes in the offspring (24, 25). It should be noted that reduced birth weight is not an obligatory consequence of prenatal glucocorticoid administration in rodents but appears mainly with late-gestational exposure when fetal growth is maximal (26).

Further human studies extended the low-birth-weight baby phenotype to include altered HPA axis function later in life as an outcome (27). Interestingly, high levels of cortisol in mothers are correlated with low birth weight of their offspring (28). Further, severe stress in pregnancy (exposure to the World Trade Center attacks of September 11, 2001) doubled the incidence of intrauterine growth retardation and affected salivary cortisol levels in the offspring of mothers who developed posttraumatic stress disorder; these effects were largely confined to individuals exposed in
Results

Pregnancy. Dexamethasone dose-dependently reduced the circulating levels of cortisol in maternal blood at 22 weeks of pregnancy ($P < 0.0001$), suggesting that it was absorbed and affected at least the maternal HPA axis (Table 1). However, other than suppressing maternal cortisol levels, dexamethasone had no obvious effects on the pregnant females, whose apparent well-being, as assessed by weight gain in pregnancy, maternal blood pressure, plasma electrolytes, and glucose levels, was unaffected by dexamethasone treatment (Table 2).

Dexamethasone significantly reduced fetal femoral length and, less clearly, altered placental thickness (Table 3). No dose of dexamethasone had any effect on fetal heart rate, biparietal diameter, or abdominal diameter at 12 and 22 weeks of pregnancy (Table 3). Gestation length was unaffected by dexamethasone (controls, 204 ± 5 days from start of last menstruation; 50 μg/kg/day dexamethasone [dex50], 204 ± 6 days; 120 μg/kg/day dexamethasone [dex120], 205 ± 4 days; 200 μg/kg/day dexamethasone [dex200], 200 ± 4 days). Fetal survival was affected by dexamethasone, but only at the highest dose; dex200 was associated with increased stillbirths (dex200, 31.3%; control, 0%; $P < 0.05$, $\chi^2$ test; Table 3).

Table 1
Maternal plasma cortisol levels just before (12 wk gestation) and during (22 wk gestation) oral dexamethasone or vehicle (control) administration

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Dexamethasone</th>
<th>Dexamethasone</th>
<th>Dexamethasone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 16</td>
<td>n = 8</td>
<td>n = 12</td>
<td>n = 16</td>
</tr>
<tr>
<td>Cortisol levels before treatment, 12 wk gestation</td>
<td>955 ± 67</td>
<td>1,102 ± 98</td>
<td>1,073 ± 73</td>
<td>1,011 ± 88</td>
</tr>
<tr>
<td>On treatment, 22 wk gestation</td>
<td>1,374 ± 57</td>
<td>881 ± 129</td>
<td>785 ± 64</td>
<td>524 ± 95</td>
</tr>
<tr>
<td>Bonferroni versus control</td>
<td>P &lt; 0.01</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
</tr>
</tbody>
</table>

Two-way ANOVA: interaction between time and dexamethasone, $F_{3,96} = 13.48$, $P < 0.0001$; dexamethasone, $F_{3,96} = 9.55$, $P < 0.0001$. There were no differences between groups before treatment (12 weeks), whereas all dexamethasone groups were significantly less than control at 22 weeks. $P < 0.01$ for all dexamethasone groups (Bonferroni’s multiple-comparison test).

Table 2
Effect of prenatal dexamethasone on maternal parameters

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Dexamethasone</th>
<th>Dexamethasone</th>
<th>Dexamethasone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 13</td>
<td>n = 13</td>
<td>n = 13</td>
<td>n = 13</td>
</tr>
<tr>
<td>Maternal weight (kg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preconception</td>
<td>3.60 ± 0.18</td>
<td>3.33 ± 0.12</td>
<td>3.50 ± 0.11</td>
<td>3.48 ± 0.10</td>
</tr>
<tr>
<td>Before treatment, 12 wk</td>
<td>4.07 ± 0.11</td>
<td>3.90 ± 0.16</td>
<td>4.05 ± 0.10</td>
<td>4.24 ± 0.11</td>
</tr>
<tr>
<td>On treatment, 22 wk</td>
<td>4.51 ± 0.12</td>
<td>4.48 ± 0.25</td>
<td>4.54 ± 0.09</td>
<td>4.66 ± 0.11</td>
</tr>
<tr>
<td>Maternal 24-hour urine volume (ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before treatment, 12 wk</td>
<td>71.5 ± 9.3</td>
<td>64.7 ± 15.0</td>
<td>67.3 ± 10.7</td>
<td>62.4 ± 5.3</td>
</tr>
<tr>
<td>On treatment, 22 wk</td>
<td>71.6 ± 10.8</td>
<td>74.2 ± 13.0</td>
<td>56.4 ± 6.1</td>
<td>62.4 ± 11.2</td>
</tr>
<tr>
<td>Maternal blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic before treatment, 12 wk</td>
<td>90.2 ± 2.8</td>
<td>90.3 ± 2.5</td>
<td>96.5 ± 3.4</td>
<td>98.2 ± 5.7</td>
</tr>
<tr>
<td>Systolic on treatment, 22 wk</td>
<td>92.5 ± 3.2</td>
<td>92.1 ± 2.3</td>
<td>92.6 ± 7.9</td>
<td>97.3 ± 3.3</td>
</tr>
<tr>
<td>Diastolic before treatment, 12 wk</td>
<td>48.5 ± 3.4</td>
<td>46.1 ± 4.0</td>
<td>52.6 ± 2.1</td>
<td>52.7 ± 4.3</td>
</tr>
<tr>
<td>Diastolic on treatment, 22 wk</td>
<td>49.6 ± 2.4</td>
<td>47.0 ± 1.8</td>
<td>54.5 ± 2.7</td>
<td>54.1 ± 2.7</td>
</tr>
<tr>
<td>Maternal plasma electrolytes (mM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium before treatment, 12 wk</td>
<td>146.0 ± 0.7</td>
<td>145.5 ± 1.1</td>
<td>143.3 ± 0.7</td>
<td>144.3 ± 0.5</td>
</tr>
<tr>
<td>Sodium on treatment, 22 wk</td>
<td>142.2 ± 0.7</td>
<td>143.3 ± 1.1</td>
<td>142.1 ± 0.7</td>
<td>143.5 ± 0.6</td>
</tr>
<tr>
<td>Potassium before treatment, 12 wk</td>
<td>3.7 ± 0.1</td>
<td>3.7 ± 0.3</td>
<td>3.3 ± 0.1</td>
<td>3.7 ± 0.1</td>
</tr>
<tr>
<td>Potassium on treatment, 22 wk</td>
<td>3.2 ± 0.2</td>
<td>3.0 ± 0.1</td>
<td>3.3 ± 0.2</td>
<td>3.6 ± 0.2</td>
</tr>
<tr>
<td>Chloride before treatment, 12 wk</td>
<td>108.9 ± 0.9</td>
<td>106.8 ± 3.3</td>
<td>108.2 ± 0.6</td>
<td>108.4 ± 0.6</td>
</tr>
<tr>
<td>Chloride on treatment, 22 wk</td>
<td>109.1 ± 1.0</td>
<td>106.8 ± 1.4</td>
<td>107.2 ± 0.7</td>
<td>108.9 ± 0.7</td>
</tr>
</tbody>
</table>

No statistically significant differences.
nental glucocorticoids (Table 5). Kruskal-Wallis testing supported a diminished motor activity at a higher dose of prenatal dexamethasone ($P = 0.007$).

**Gross measurements at 12–14 months.** A subset of animals was sacrificed at 12–14 months of age. Organ weights (gross as well as relative to total body weight) of the left and right adrenals, thymus, left and right kidneys, heart, and brain were not affected by antenatal glucocorticoid exposure. Pituitary weight was increased in dex200 offspring ($P = 0.05$ versus control; data not shown).

**Insulin and glucose.** Oral glucose tolerance tests were performed in 8-month-old offspring after an overnight fast. Offspring of dex120 pregnancies had higher fasting plasma insulin levels (Figure 1). Insulin increased to greater extent after glucose tolerance tests in dex120 and dex200 offspring as compared with controls (Figure 1). Fasting and peak glucose levels were similar in all groups, but subsequent glucose clearance was significantly slower in the dex120 and dex200 offspring (Figure 1), and there was a similar trend in the dex50 offspring ($P = 0.051$).

**Pancreas.** There was a pronounced reduction in the number of $\beta$ cells compared with total cell number ($\alpha$ and $\beta$ cell number combined) in the pancreatic islets of 12- to 14-month-old offspring of dex120 and dex200 pregnancies compared with controls (Figure 2). Moreover, dex120 and dex200 offspring showed smaller insulin-producing $\beta$ cells than controls (controls, 116 ± 11 mm$^2$; dex50, 90 ± 22 mm$^2$; dex120, 52 ± 3 mm$^2$; dex200, 48 ± 2 mm$^2$; $P < 0.002$), while $\alpha$ cell size was unaltered (controls, 146 ± 26 mm$^2$; dex50, 106 ± 23 mm$^2$; dex120, 141 ± 5 mm$^2$; dex200, 142 ± 3 mm$^2$), resulting in a smaller $\beta$ cell/$\alpha$ cell area ratio. Dex50 had no effect on $\beta$ cell parameters.

**Liver.** The key hepatic gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK) and one of its major regulating transcription factors, the glucocorticoid receptor (GR), were estimated on the basis of previous rodent findings with antenatal dexamethasone (26). PEPCK activity as well as mRNA was reduced in dex120 and dex200 offspring livers (Figure 3), and, as expected, PEPCK mRNA and activity were correlated ($r = 0.63$, $P = 0.01$). PEPCK mRNA and GR mRNA contents in the liver were also interrelated and affected by the different prenatal dexamethasone treatments (Figure 3; 2-way ANOVA for PEPCK and GR mRNA, $F_{(3,12)} = 3.96$; interaction between offspring groups and PEPCK and GR mRNA, $P = 0.036$).

**Blood pressure.** Blood pressure was measured in the offspring of control and dexamethasone-treated mothers at 8 and again at 12–14 months of age. Whereas systolic and diastolic pressures were similar in all groups at 8 months (Figure 4), by 12–14 months dex120 and dex200 offspring showed a significant increase in systolic (+12 and +17 mmHg, respectively) and diastolic (+18 and +17 mmHg, respectively) pressure as compared with controls (Figure 4). Dex50 offspring showed a small but significant decrease in systolic pressure (by 9 mmHg) at 12–14 months, but diastolic pressure was unaffected.

**Cortisol and its metabolites.** Mild stress, induced by blood sampling, produced an elevation of the plasma cortisol levels to a significantly greater extent in dex200 offspring than in controls (Figure 5). To test negative feedback, infants at 12–14 months were given a dexamethasone suppression test, but this showed no difference in morning cortisol levels between controls and different prenatal dexamethasone treatments (plasma cortisol levels 9 hours after 0.026 mg/kg dexamethasone given at 7 am were: controls, 1,887 ± 168 nmol/l; dex50, 1,501 ± 258 nmol/l; dex120, 1,387 ± 146 nmol/l; and dex200, 1,736 ± 227 nmol/l; NS).

**Tissue metabolism of cortisol may alter plasma levels.** However, 24-hour urinary collections and gas chromatographic/mass spectrometric analysis revealed no group differences in the levels of cortisol, cortisone, tetrahydrocortisols, tetrahydrocortisone,

Table 3

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Dex50</th>
<th>Dex120</th>
<th>Dex200</th>
<th>Interaction time/dex</th>
<th>Dex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placental thickness (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No dex, 12 wk</td>
<td>9.8 ± 0.4</td>
<td>10.7 ± 0.6</td>
<td>10.2 ± 0.4</td>
<td>9.7 ± 0.5</td>
<td>3.52$^A$</td>
<td></td>
</tr>
<tr>
<td>On dex, 22 wk</td>
<td>14.0 ± 0.8</td>
<td>13.3 ± 0.6</td>
<td>13.2 ± 0.7</td>
<td>15.3 ± 0.5</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Fetal heart rate (bpm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No dex, 12 wk</td>
<td>154 ± 3</td>
<td>161 ± 2</td>
<td>171 ± 7</td>
<td>173 ± 5</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>On dex, 22 wk</td>
<td>159 ± 2</td>
<td>155 ± 4</td>
<td>164 ± 8</td>
<td>169 ± 6</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Biparietal diameter (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No dex, 12 wk</td>
<td>26.1 ± 0.9</td>
<td>25.7 ± 0.7</td>
<td>26.5 ± 1.2</td>
<td>28.4 ± 1.0</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>On dex, 22 wk</td>
<td>41.0 ± 0.7</td>
<td>43.5 ± 0.3</td>
<td>43.4 ± 0.6</td>
<td>43.1 ± 0.5</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Abdominal diameter (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No dex, 12 wk</td>
<td>19.1 ± 0.9</td>
<td>20.5 ± 0.8</td>
<td>17.9 ± 0.7</td>
<td>18.4 ± 0.9</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>On dex, 22 wk</td>
<td>31.7 ± 0.9</td>
<td>29.5 ± 1.7</td>
<td>32.8 ± 0.9</td>
<td>29.7 ± 1.1</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Femur length (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No dex, 12 wk</td>
<td>14.1 ± 0.6</td>
<td>14.8 ± 0.8</td>
<td>14.2 ± 0.7</td>
<td>14.5 ± 0.7</td>
<td>4.26$^A$</td>
<td>3.16$^A$</td>
</tr>
<tr>
<td>On dex, 22 wk</td>
<td>41.1 ± 2.1</td>
<td>39.8 ± 3.3</td>
<td>31.2 ± 2.9$^A$</td>
<td>31.7 ± 2.5$^A$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Fetal survival</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abortion no. (%) of total live births</td>
<td>1 (6.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>2 (12.5%)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Stillbirth no. (%) of total live births</td>
<td>0 (0%)</td>
<td>1 (16.7%)</td>
<td>1 (7.7%)</td>
<td>5 (31.3%)$^A$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Live birth no. (%) of total pregnancies</td>
<td>16 (93.8%)</td>
<td>6 (85.7%)</td>
<td>13 (92.9%)</td>
<td>16 (69.6%)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>No. alive at 12 mo (%) of live births</td>
<td>13 (87.7%)</td>
<td>6 (100%)</td>
<td>13 (100%)</td>
<td>13 (81.3%)</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

$^A P < 0.05$; 2-way repeated-measures ANOVA with post hoc Bonferroni’s multiple-comparison test, except fetal survival data, which were analyzed with $\chi^2$ versus control (alive/stillbirth). Dex, dexamethasone.
### Table 4

**Effects of prenatal maternal exposure to oral dexamethasone or vehicle (control) on anthropometric parameters in newborns and infants**

<table>
<thead>
<tr>
<th>Control</th>
<th>Dexamethasone (Dex50)</th>
<th>Dexamethasone (Dex120)</th>
<th>Dexamethasone (Dex200)</th>
<th>Interaction time/dex</th>
<th>F&lt;sub&gt;1,28&lt;/sub&gt; (P&lt;sub&gt;0.05&lt;/sub&gt;)</th>
<th>F&lt;sub&gt;2,28&lt;/sub&gt; (P&lt;sub&gt;0.05&lt;/sub&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (g)</td>
<td>n = 13</td>
<td>n = 6</td>
<td>n = 13</td>
<td>n = 13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 mo</td>
<td>323 ± 9</td>
<td>350 ± 18</td>
<td>320 ± 9</td>
<td>306 ± 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 mo</td>
<td>568 ± 21</td>
<td>605 ± 30</td>
<td>571 ± 23</td>
<td>551 ± 37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 mo</td>
<td>635 ± 28</td>
<td>727 ± 26</td>
<td>750 ± 24</td>
<td>699 ± 32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mo</td>
<td>852 ± 35</td>
<td>832 ± 16</td>
<td>875 ± 31</td>
<td>862 ± 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 mo</td>
<td>1,068 ± 33</td>
<td>1,003 ± 17</td>
<td>1,001 ± 33</td>
<td>1,000 ± 31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td>1,395 ± 50</td>
<td>1,347 ± 64</td>
<td><strong>1,308 ± 37</strong></td>
<td></td>
<td><strong>1,215 ± 44</strong></td>
<td></td>
</tr>
</tbody>
</table>

*Significant differences from controls are shown in boldface. *P* < 0.001, *P* < 0.05, *P* < 0.01 versus control. Last 2 columns: 2-way repeated-measures ANOVA. In cells, post hoc testing by Fisher’s least significant difference method for factor versus control.*
Natal dexamethasone had no discernible effects on most fetal parameters. However, femur length was reduced by dexamethasone — length has distinct associations in the human epidemiological canon, notably with lifespan and cardiovascular disorders (37) — demonstrating at least 1 fetal growth–retarding action, as previously reported in primates (38). Placental thickness was also altered by dexamethasone, though lower doses tended to thin the placenta whereas dex200 thickened it; such dose-related inconsistent effects of glucocorticoids on placental size have been noted previously (39) but are of uncertain significance. The highest dose of dexamethasone increased stillbirth, mirroring anecdotal human reports (40, 41) and findings in monkeys (42).

Intriguingly, weight and other parameters at birth were also unaltered by dexamethasone. This contrasts with several rodent programming models using dexamethasone, stress, and 11β-HSD2 inhibition, all of which reduce birth weight (15, 22, 25). However, mid- to late-gestational stress in rhesus monkeys also fails to alter birth weight (43), and guinea pigs resist changes in birth weight following maternal food restriction, though this stimulus has programming effects on offspring’s cardiometabolic and neuroendocrine functions (44). In humans, antenatal glucocorticoids have been associated with reduced birth weight (45, 46), but fetuses at risk of congenital adrenal hyperplasia, whose mothers have received relatively low-dose dexamethasone throughout pregnancy, usually have normal birth weight (47, 48). Of course, birth weight and other anthropometric indices are relatively crude measures of organ growth and function, but the findings, set against altered offspring physiology, emphasize that antenatal insults do not need to affect birth weight in order to exert significant programming effects on cardiovascular or metabolic function.

As in rodents (7), low-dose dexamethasone, other than maternal HPA axis suppression, had few obvious effects on pregnant females; weight gain, blood pressure, plasma electrolytes, and glucose levels were unaffected. Along with results in 11β-HSD2−/− (heterozygous) mouse crosses showing that behavioral programming follows the fetal/placental genotype in littermates (22), these data imply that glucocorticoids probably act on the fetoplacental unit rather than via altered maternal pathophysiology.

Table 5
Neurodevelopmental effects of antenatal exposure to dexamethasone or vehicle as reflected in Brazelton scores in neonatal offspring

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Dex50</th>
<th>Dex120</th>
<th>Dex200</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>13</td>
<td>6</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Palmar grasp response</td>
<td>1.92 ± 0.08</td>
<td>2.00 ± 0.00</td>
<td>1.92 ± 0.08</td>
<td>1.91 ± 0.09</td>
</tr>
<tr>
<td>Plantar grasp response</td>
<td>1.92 ± 0.08</td>
<td>1.83 ± 0.17</td>
<td>1.83 ± 0.11</td>
<td>1.91 ± 0.09</td>
</tr>
<tr>
<td>Body righting</td>
<td>1.85 ± 0.15</td>
<td>1.67 ± 0.33</td>
<td>1.83 ± 0.17</td>
<td>1.64 ± 0.20</td>
</tr>
<tr>
<td>Resistance to passive movement</td>
<td>1.77 ± 0.12</td>
<td>2.00 ± 0.00</td>
<td>1.67 ± 0.19</td>
<td>1.82 ± 0.18</td>
</tr>
<tr>
<td>Active power</td>
<td>1.77 ± 0.12</td>
<td>2.00 ± 0.00</td>
<td>1.33 ± 0.23</td>
<td>1.64 ± 0.20</td>
</tr>
<tr>
<td>Tactile response</td>
<td>2.00 ± 0.00</td>
<td>2.00 ± 0.00</td>
<td>1.92 ± 0.83</td>
<td>2.00 ± 0.00</td>
</tr>
<tr>
<td>Spontaneous locomotion</td>
<td>1.31 ± 0.21</td>
<td>1.00 ± 0.26</td>
<td>1.58 ± 0.19</td>
<td>1.73 ± 0.41</td>
</tr>
<tr>
<td>Motor activityA</td>
<td>2.00 ± 0.00</td>
<td>2.00 ± 0.00</td>
<td>1.42 ± 0.19A</td>
<td>1.73 ± 0.41</td>
</tr>
</tbody>
</table>

Kruskal-Wallis testing shows diminished motor activity in offspring following the higher doses of prenatal dexamethasone; \( P = 0.007 \). Mann-Whitney \( U \) post hoc testing, \( *P < 0.05 \).

Figure 1
Intravenous glucose tolerance tests in offspring of dexamethasone- and control-treated pregnancies. (A–C) Plasma glucose levels before (time = 0) and during an i.v. glucose tolerance test. Overall glucose clearance was affected by antenatal dexamethasone treatment (2-way ANOVA, \( F_{(3,244)} = 4.4, P = 0.005 \)). The glucose clearance was slower in the dex120 and dex200 offspring than in controls (post hoc testing, Fisher’s least significant difference method for factor, \( *P < 0.02 \) for dex120 and dex200; \( P = 0.051 \) for dex50). (D) Insulin levels of 8-month-old offspring before and 10 minutes after i.v. glucose administration. Basal insulin levels were increased in dex120 offspring (\( *P < 0.05 \) versus control; 2-tailed Student’s \( t \) test). At 10 minutes, plasma insulin was elevated in dex120 and dex200 offspring (\( *P < 0.05 \) versus control; 2-tailed Student’s \( t \) test).
Previous reports document that antenatal stress or glucocorticoid exposure alters offspring behavior and CNS structure (49–51). While, at birth, behavior was largely similar in control and dexamethasone-exposed offspring, the motor subset of Brazelton scores showed significant retardation in dexamethasone-exposed offspring. Such findings parallel motor retardation seen in early-postnatal 11β-HSD2–/– mice (52) but have not been reported, at least as determined by maternal questionnaire, following low-dose dexamethasone in early gestation in antenatal therapy for congenital adrenal hyperplasia risk (53). Since the Brazelton score is a clinical tool based on sensorimotor function at birth, the data here do not confirm that antenatal dexamethasone in late gestation has no effects on the developing primate CNS. However, the Brazelton score has limited predictive value, and it would be interesting to reanalyze sensorimotor function later in life.

Prenatal dexamethasone and later pathophysiology. While prenatal dexamethasone had only a few, relatively subtle actions on morphology at birth, thereafter persisting effects were clear-cut. Both dex120 and dex200 attenuated postnatal growth and increased subcutaneous fat. There were also clear effects on glucose-insulin homeostasis, pancreatic endocrine structure, blood pressure, and HPA axis activity. However subtle, these effects were detectable even in very young animals. The effects of early-life manipulations in rodents and the birth weight observations in humans suggest amplification of phenotypes with aging and with adult challenges, notably obesity (54).

Abnormal glucose tolerance was observed in dexamethasone-treated offspring, notably, delayed glucose clearance, likely mediated by reduced peripheral glucose uptake. This was not due to frank obesity; indeed, the dexamethasone-treated offspring were lighter, though increased fat mass may have contributed (juvenile monkeys are very lean). As well as delayed glucose clearance, in rats (26) and sheep (55) fasting hyperglycemia is reported after antenatal dexamethasone, stress, or 11β-hydroxysteroid dehydrogenase inhibition. This was not seen here, but the monkeys are prepubertal, and perhaps other defects in glucose tolerance will become manifest as they age, as observed in some rodent models (56). The data here suggest that delayed glucose clearance is an early abnormality in dexamethasone-programmed primates. The increased insulin release in response to glucose challenge in dex120 and dex200 offspring supports the notion of early insulin resistance. However, the reduction of pancreatic β cell number and size at 1 year suggests that the extent of any compensatory hyperinsulinemia will be limited, risking type 2 diabetes over and above any later loss of β cell function (57). Interestingly, fasting insulin levels rose in response to dextrose loading in dex120 but not in dex200 offspring (Figure 1), which may point to an earlier β cell decompensation following higher-dose exposure. Antenatal glucocorticoids have been previously reported to reduce β cell mass in adult mice (58) and rats (10), and in rhesus fetuses (59), in line with our finding in juvenile vervets. Intriguingly, brief late-gestational exposure to glucocorticoids in humans associates with postglucose hyperinsulinemia more than 3 decades later (31).

In previous rat studies, hepatic PEPCK was increased in the offspring of dexamethasone-exposed pregnancies (9, 26). In young vervets, we find hepatic PEPCK is reduced after antenatal dexamethasone. PECK gene regulation is complex and involves interplay and that reduced PEPCK may ameliorate any tendency toward fasting hyperglycemia in these animals. GR has been proposed as a key target for antenatal glucocorticoid or nutritional

![Figure 2](image-url)

**Figure 2**
Pancreatic β cell content is reduced in the offspring of dexamethasone-treated pregnancies. The β cell content relative to the total of α and β cells in the pancreatic islets is depicted. One-way ANOVA, \( F_{(3,23)} = 18.47, P < 0.0001 \); Bonferroni’s multiple-comparison test, \(*P < 0.001\).

![Figure 3](image-url)

**Figure 3**
PECK activity in the liver is diminished in the offspring of pregnant animals given dexamethasone, coinciding with attenuated PECK mRNA and altered GR mRNA expression. Top left: PECK activity in the liver. One-way ANOVA, \( P = 0.0096 \); Newman-Keuls multiple-comparison test, \(*P < 0.05\) versus control. Bottom left: Relative PECK mRNA content in the liver. Two-way ANOVA for PECK and GR mRNA, \( F_{(3,12)} = 3.96 \); interaction between PECK and GR mRNA, \( P = 0.036 \).

The increased insulin release in response to glucose challenge in dex120 and dex200 offspring supports the notion of early insulin resistance. However, the reduction of pancreatic β cell number and size at 1 year suggests that the extent of any compensatory hyperinsulinemia will be limited, risking type 2 diabetes over and above any later loss of β cell function (57). Interestingly, fasting insulin levels rose in response to dextrose loading in dex120 but not in dex200 offspring (Figure 1), which may point to an earlier β cell decompensation following higher-dose exposure. Antenatal glucocorticoids have been previously reported to reduce β cell mass in adult mice (58) and rats (10), and in rhesus fetuses (59), in line with our finding in juvenile vervets. Intriguingly, brief late-gestational exposure to glucocorticoids in humans associates with postglucose hyperinsulinemia more than 3 decades later (31).

In previous rat studies, hepatic PEPCK was increased in the offspring of dexamethasone-exposed pregnancies (9, 26). In young vervets, we find hepatic PEPCK is reduced after antenatal dexamethasone. PECK gene regulation is complex and involves interplay among insulin, glucocorticoids, and other counterregulatory hormones (60). In rats, several transcription factors involved in PECK control are altered by antenatal dexamethasone (61). We suggest that the changes in PECK in vervet offspring reflect this interplay and that reduced PECK may ameliorate any tendency toward fasting hyperglycemia in these animals. GR has been proposed as a key target for antenatal glucocorticoid or nutritional
programming (62, 63). The trend of increased GR in liver here, paralleling similar significant findings in rats, suggests that similar broad principles operate in primates. Indeed, the structure of the GR gene promoter with alternate tissue-specific untranslated first exons is conserved in rodents and humans (64, 65).

As in other species (7, 12, 66), antenatal dexamethasone in the vervet produced hypertension in the juvenile offspring. Prenatal exposure to dexamethasone has previously been shown to elevate fetal and neonatal blood pressure in baboons (67–69) and in adolescent humans (30). The mechanisms of early-life programming of elevated blood pressure are unknown but, in rodent models, have been ascribed to variations in nephron number, vascular sensitivity to vasoconstrictors, and hyperinsulinemia (70–72). Urinary steroid profiling does not suggest that altered renal 11β-HSD2 contributes to the hypertension.

Finally, the highest dose of dexamethasone also increased activation of the offspring HPA axis, at least under the stress of sampling, reflecting findings in other models of prenatal programming in a variety of species and at the diurnal maximum in low-birth-weight children and adults (refs. 27, 72; reviewed in ref. 73). Interestingly, in rhesus monkeys, stress during pregnancy also programs increased HPA activity in the offspring (74). After the World Trade Center attacks of September 11, 2001, mothers who developed posttraumatic stress disorder showed lower cortisol levels, and most interestingly, so did their babies, with the effects mostly confined to those exposed in later pregnancy (29). Mechanistically, both dexamethasone suppression (testing GR sensitivity in the anterior pituitary and, less certainly, the CNS) and basal cortisol production and metabolism were unaltered. While no test is faultless, these data suggest that the exaggerated cortisol response to stress after prenatal dexamethasone reflects increased drive rather than attenuated feedback. This contrasts with altered feedback seen in rats and other species with late-gestational dexamethasone exposure (15). In rodents, the central mechanisms of HPA axis hyperactivity depend on the window of steroid exposure during pregnancy (7, 15). Human brain subregions develop at different times to analogous structures in rodents, so the differing mechanisms of dexamethasone HPA axis programming implied are not unexpected.

These data do not reveal whether the dexamethasone-programmed phenotype will persist into adult life and, if so, whether it will be exacerbated or attenuated with age; ongoing followup of the offspring may resolve this point. Data from shorter-lived models and human epidemiology suggest that the changes will diverge further from controls with aging and adult challenges such as obesity (31, 54, 75).

In sum, in a nonhuman primate model of singleton pregnancy, antenatal exposure to low doses of dexamethasone, which had no significant effect on birth weight or other anthropometric parameters, produced disordered glucose-insulin homeostasis, reduced pancreatic β cell mass, and elevated blood pressure and cortisol levels in juvenile offspring. The data are compatible with the extrapolation of the glucocorticoid programming hypothesis to primates.

Methods

Animals. All animals selected for this study were healthy adult vervet monkeys (Chlorocebus aethiops), also known as African green monkeys, and part of a captive-bred indoor colony at the Primate Unit of the South African Medical Research Council. Forty animals were multiparous females with an average weight of 3.35 ± 0.42 kg, and 13 were males with an average weight of 4.78 ± 0.92 kg. All were selected for normal blood pressures and glucose tolerance with the use of reference data established for this colony. The monkeys were permanently identified with numbers in ink tattoo.

Housing. For the duration of the study, all monkeys were maintained under identical housing conditions as described previously (76, 77). In short, the air was changed between 15 and 20 times each hour, the temperature was kept at 25°C, the humidity was 50%, and light and dark phases both lasted 12 hours. To enable mating, the animals were maintained in pairs, and then the females were housed singly during pregnancy and lactation. All individually housed animals had access to exercise cages and for-
aging material 3 times per week. Bird sounds were piped into every room.
After weaning at 8 months, the offspring were kept in pairs for behavioral
observations, then placed in peer groups of 6 same-sex individuals from 10
months to 12 months of age.

Pregnancy diagnosis and monitoring. Females were paired with males regard-
less of the stage of the menstrual cycle, and pregnancies were confirmed,
dated, and monitored ultrasonographically as described by Seier et al. (78)
for vervet monkeys. To diagnose pregnancy, the females were examined
once a month under ketamine anesthesia at 10 mg/kg body weight. A ges-
tational sac 2 mm in width is the first sign of pregnancy in vervet monkeys
and indicates an embryo of about 33 days’ menstrual age (78). The ges-
tational sac dimension was measured with electronic calipers, and these
measurements, as well as features such as size and date of first appear-
ance of the yolk sac and first appearance of fetal heartbeat, were used as a
basis for calculating the menstrual age of the pregnancy. This method was
also used to determine a date for the start of the glucocorticoid treatment.
The gestation period in vervet monkeys is about 5.5 months (79, 80). The
gestational age was determined by previously established intrarectal digi-
tal and ultrasonographic techniques for vervet monkey pregnancies (77,
78). Pregnant vervets were monitored ultrasonically at weeks 12 and 22
to determine thickness of placenta, fetal heart rate, abdominal diameter,
and femur length. Also at 12 and 22 weeks, blood samples were taken to
determine anions and cortisol.

Treatments. The females were randomly divided into 4 groups, 3 of which
were given dexamethasone at 50, 120, or 200 μg/kg/d (denoted as dex50,
dex120, and dex200) from mid-gestation onward. Dexamethasone was
discontinued after birth. The dose of dexamethasone is not dissimilar to
doses used in human pregnancy, which vary from 20 μg/kg/d in congenital
adrenal hyperplasia (33, 48, 53) to 100–200 μg/kg/d in threatened preterm
labor (30, 31, 35, 45, 46). The dexamethasone was administered daily
in food, which consisted of precooked maize meal containing micro-mac-
ronutrient supplementation, as described previously (81). The diet has
supported normal reproduction and development for 2 generations (76).
Compliance was determined indirectly by determination of the anticipated
suppression of maternal plasma cortisol by dexamethasone twice during
pregnancy (as described below).

Interventions, tests, and measurements. Weight, head circumference, head
length, biparietal diameter, crown-heel length, crown-rump length,
abdominal circumference, subcutaneous fat thickness, femur length, tibia
length, forearm length, and hip width were measured at birth with the use
of tape and calipers, and at 2, 4, 6, 8, and 12 months of age. The ponderal
index and Brazelton score were determined at birth. Blood was sampled
from infant offspring via the femoral vein under ketamine anesthesia
(10 mg/kg body weight, intramuscularly). Ketamine was delivered under
brief physical restraint in the home cage.

Adapted Brazelton score at birth. An adapted Brazelton score based on vari-
ous individual measures was used as an indication of motor function at
birth. These measures, followed by the score measures, included the follow-
(а) Palmar grasp response: place index finger in palm; 0, no grasping
reflex; 1, partial grasp; 2, strong reflexive grasp without voluntary release. (b)
Plantar grasp response: place index finger under foot; 0, no grasping reflex;
1, partial grasp; 2, strong reflexive grasp without voluntary release. (c) Body
righting: time noted for the infant to turn from supine to prone; 0; par-
tial righting; 1, righting in 5 seconds; 2, righting in less than 5 seconds. (d)
Resistance to passive movement: degree of resistance to passive flexion
and extension of limbs; 0, barely discernible resistance; 1, moderate resistance;
2, strong resistance. (e) Active power: strength of muscles when actively
contracting; 0, some strength but cannot withstand slight resistance;
1, withstands moderate resistance; 2, extremely strong. (f) Tactile response:
response to tactile stimulus to the 4 extremities (with a cotton swab); 0,
no response; 1, barely discernible response; 2, easily apparent response. (g)
Spontaneous locomotion: quality of locomotion within 1 minute; 0, none;
1, a weak attempt at crawling; 2, coordinated crawling noted. (h) Motor
activity: observation of motor activity throughout the observation period.

Ponderal index. The ponderal index relates weight (in grams) to height (in
cm). The index is calculated as (weight/height3) × 100.

Intravenous glucose tolerance tests. Glucose tolerance was determined in
the offspring at 8 months of age. Serial blood sampling was obtained via
an i.v. catheter inserted into the saphenous vein under aseptic conditions
and connected to a drip set containing physiological saline to maintain
patency. After obtaining a baseline blood sample for glucose and insulin,
1 ml/kg of 50% dextrose was administered i.v. Further sampling for blood
glucose occurred 5, 10, 15, 20, 40, and 60 minutes after dextrose. A sample
for plasma insulin was taken at 10 minutes. Glucose was analyzed by an
enzymatic essay (Bayer T01-1825-56) and insulin by microparticle enzyme
immunoassay (AxSYM B2D010; Abbott Diagnostics).

Dexamethasone suppression test. The suppression test was conducted in the
offspring at 8 and 12 months. A basal blood sampling at 10:00 pm was
followed by an i.v. administration of 0.026 mg/kg dexamethasone.
A second sample was obtained at 7:00 am. All samples were analyzed for
cortisol as described above.

Organ weights. At 12–14 months, vervets were killed, and part of the liver
and pancreas, and the whole heart, kidney, adrenal, brain, pituitary, and
thymus, were removed to determine organ weight and for further examination.

PEPCK activity. At 12–14 months, part of the liver was snap-frozen to
determine PEPCK activity as described previously (26, 82). In short, liver
tissue was homogenized and the cytosolic fraction obtained. The cytosolic
fraction (1 mg) was assayed in 1 ml buffer containing 50 mM HEPES
(pH 6.5), 50 mM sodium bicarbonate, 1 mM MgCl2, 0.25 mM NADH, 1.0
mM phosphoenolpyruvate, and 1.5 U malate dehydrogenase. The absorb-
bance of NADH was determined at 340 nm at 30°C. After a stable signal
was obtained, the reaction was initiated by addition of 0.15 mM 2-deoxy-
guanosine 5’-diphosphate. After 3 minutes of incubation, the decrease in
absorbance was measured at a wavelength of 340 nm. The assay was per-
formed in duplicate for all samples. A reaction mixture without bicarbon-
ate was used as a negative control.

Real-time PCR. RNA was extracted from frozen liver aliquots with the use of
TRIZol (Invitrogen). The isolated RNA was reverse-transcribed to obtain
cDNA with the use of a Reverse Transcriptase kit (Reverse Transcriptase
[RT] system; Promega). PECK and GRα mRNA were quantified with
RT-PCR primer-probe sets with the use of the ABI PRISM 7900 Sequence
Detection System (PE Applied Biosystems) with the following primers and
probes: GRα: 5′-CATTGTCAAGAGGGAAGGAACTC-3′ (forward),
5′-GATTTCACACCTCCATGACAAAGA-3′ (reverse), and 5′-FAM-
TTGTCAAGCATTTAGAGACTGCT-5′ (probe). 18S ribosomal RNA primers and probes (Applied Biosystems) were used to
normalize the transcript levels. A standard curve for each primer-probe set
was generated in triplicate by serial dilution of cDNA that was pooled from
several subjects. Each sample was run in duplicate, and the mean values of
the duplicates were used to calculate the transcript level from the standard
curve. The results are expressed as arbitrary units.

Pancreas histology. Pancreata were placed in 4% paraformaldehyde over
night and processed in an automated tissue processor (Shandon Citadel
1000; Thermo Scientific) through ascending concentrations of ethanol
from 70%–100%, followed by xylene. The tissue was embedded in paraffin
wax (Paraplast Plus; Monoject Scientific). Sections 4 μm thick were cut on
a rotary microtome and mounted on slides coated with 3-aminopropyl-
triethoxysilane. Serial sections were incubated for 5 minutes in 0.228%
periodic acid to inhibit endogenous peroxidases. In each section, α cells
were immunolabeled first, with a polyclonal glucagon antibody (Dako)
for 30 minutes at room temperature followed by 9.05% dianisomethylamine. Then β-cells were labeled with a monoclonal insulin antibody, overnight at 4°C (Sigma-Aldrich), followed by avidin-biotin-peroxidase complex (VECTORSTAIN; Vector Laboratories). Fuchsin (Dako) was used to reveal the immunolabeled insulin-secreting β cells. In the method controls, primary antibody was omitted. All sections were counterstained with hematoxylin.

Blood pressure measurements. Blood pressure measurements were obtained with a Dinamap pediatric blood pressure machine as previously used in primates (83). Measurements were taken at 8 and 12 months of age, and the average of 5 measurements was used as a measure for blood pressure. These were obtained under ketamine anesthesia (10 mg/kg, intramuscularly); the monkeys were in a supine position with a cuff around their left upper arm.

24-Hour urine collection. Urine was collected for 24 hours by placement of a funnel covering the entire floor area of the cage. Cortisol and its metabolites were measured in urine by electron impact gas chromatography/mass spectrometry following Sep-Pak C18 extraction (Waters Corp.), hydrolysis with β-glucuronidase, and formation of the methoxy-trimethylsilyl derivatives. Epipocortisol and epi-tetrahydrocortisol were used as internal standards. Total cortisol metabolite excretion was calculated as tetrahydrocortisols (THFs) + tetrahydrocortisone (THE) + cortols + cortolones. Relative metabolism by 5- and 5β-reductase was inferred from the 5β-THF/5β-THF ratio. A-ring reduction of cortisol was inferred from the ratios of THFs to cortisol and 5β-reductase activity from the ratio of THE to cortisone. Whole-body equilibrium between cortisol and cortisone, determined by the balance of tissue-specific activities of 11β-reductase and 11β-dehydrogenase, was inferred from the ratio of THFs to THE. Renal 11β-dehydrogenase activity was inferred from the urinary free cortisol/cortisone ratio (84).

Ethical consideration. The experiments were performed in accordance with the National Code for Animal Use in Research, Education, and Diagnosis and Testing of Drugs and Related Substances in South Africa. The study was approved by the Ethics Committee for Research on Animals of the South African Medical Research Council and by the Ethical Review Committee of the University of Edinburgh.

Statistics. Data were analyzed by 1- or 2-way ANOVA with repeated measures where appropriate. Post hoc tests involved either Bonferroni’s multiple-comparison test or Fisher’s least significant difference method for factor as clearly indicated. Live versus still births were analyzed by χ2. Kruskal-Wallis nonparametric testing was used to analyze Brazelton scores, followed by Mann-Whitney U testing. P < 0.05 was regarded as significantly different.

Acknowledgments

We would like to thank Ruth Andrew and Alison Ayres for their excellent assistance with the GCMS analysis. This study was funded by a grant (to J.R. Seckl) from the Welcome Trust.

Received for publication November 16, 2006, and accepted in revised form January 30, 2007.

Address correspondence to: Jonathan R. Seckl, Endocrinology Unit, University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Phone: 44-131-242-6777; Fax: 44-131-2426779; E-mail: j.seckl@ed.ac.uk.

24. Doyle, L.W., Ford, C.W., Davis, N.M., and Callan,